Health-related quality of life in chronic myeloid leukemia

Leukemia Research

Volumn 37, Issue 1, 2013, Pages 9-13

  Trask, Peter C ^a   Cella, David ^b   Powell, Christine ^a   Reisman, Arlene ^a   Whiteley, Jennifer ^a   Kelly, Virginia ^a  

^a PFIZER INC   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Advanced leukemia; Chronic myeloid leukemia; Health related quality of life; Patient reported outcomes

Indexed keywords

BOSUTINIB; DASATINIB; IMATINIB; NILOTINIB;

ADULT; AGED; ARTICLE; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; FEMALE; FUNCTIONAL ASSESSMENT OF CANCER THERAPY LEUKEMIA; HUMAN; ILLNESS TRAJECTORY; MAJOR CLINICAL STUDY; MALE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHYSICAL WELL BEING; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL (TOPIC); WELLBEING;

ADULT; AGED; FEMALE; HEALTH STATUS; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; QUALITY OF LIFE;

EID: 84870890425     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2012.09.013     Document Type: Article

References (21)

1. American Cancer Society Cancer facts and figures 2010 2010, American Cancer Society, Atlanta.
2. Baccarani M., Dreyling M. Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010, 21(Suppl. 5):v165-v167. On behalf of the ESMO Guidelines Working Group.
3. O'Brien S.G., Guilhot F., Larson R.A., et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003, 348(11):994-1004.
4. Hochhaus A., O'Brien S.G., Guilhot F., et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 2009, 23:1054-1061.
5. Talpaz M., Shah N.P., Kantarjian H., et al. Dasatinib in imatinib-resistant Philadelphia chromosome - positive leukemias. N Engl J Med 2006, 354(24):2531-2541.
6. Kantarjian H., Giles F., Wunderle L., et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome - positive ALL. N Engl J Med 2006, 354:2542-2551.
7. Kantarjian H., Giles F., Wunderle L., Bhalla K., et al. Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. Blood 2011, 117(4):1141-1145.
8. Shah N.P., Kim D.-W., Kantarjian H., et al. Potent, transient inhibition of BCR-ABL with dasatinib 100mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib. Haematologica 2010, 95:232-240.
9. Efficace F., Kemmler G., Vignetti M., Mandelli F., Molica S., Holzner B. Health-related quality of life assessment and reported outcomes in leukaemia randomised controlled trials - a systematic review to evaluate the added value in supporting clinical decision making. Eur J Cancer 2008, 44(11):1497-1506.
10. Efficace F., Cocks K., Breccia M., Sprangers M., Meyers C.A., Vignetti M., et al. Time for a new era in the evaluation of targeted therapies for patients with chronic myeloid leukemia: inclusion of quality of life and other patient-reported outcomes. Crit Rev Oncol Hematol 2011, (March). [Epub ahead of print].
11. Hahn E.A., Glendenning G.A., Sorensen M.V., et al. Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS study. J Clin Oncol 2003, 21:2138-2146.
12. Brucker P.S., Yost K., Cashy J., Webster K., Cella D. General population and cancer patient norms for the Functional Assessment of Cancer Therapy-General (FACT-G). Eval Health Prof 2005, 28:192-211.
13. Arnold B., Debb S., Bruce J., Bredle J., Cella D. Using the FACT-Leukemia subscale to evaluate quality of life in leukemia patients worldwide. Value Health 2009, 12:A282.
14. Efficace F., Baccarani M., Breccia M., Alimena G., Rosti G., Cottone F., et al. Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population. Blood 2011, (July). [Epub ahead of print].
15. Brümmendorf TH, Cortes JE, Turkina A, et al. Safety and efficacy of second-line bosutinib (SKI-606) in imatinib-resistant or -intolerant chronic phase (CP) chronic myeloid leukemia (CML). Paper presented at 15th Congress of the European Hematology Association, Barcelona, Spain, June 10-13; 2010.
16. Gambacorti-Passerini C, Kim DW, Kantarjian HM, et al. An ongoing phase 3 study of bosutinib (SKI-606) versus imatinib in patients with newly diagnosed chronic phase chronic myeloid leukemia. Paper presented at 52nd American Society of Hematology Annual Meeting and Exposition, Orlando, FL, December 4-7; 2010.
17. Cella D. The manual of the functional assessment of chronic illness therapy (FACIT) measurement system. Center on Outcomes, Research and Education, Evanston Northwestern Healthcare and Northwestern University 1997.
18. Cella D.F., Tulsky D.S., Gray G., et al. The Functional Assessment of Cancer Therapy (FACT) scale: development and validation of the general measure. J Clin Oncol 1993, 11(3):570-579.
19. Cella D, Webster K, Beaumont J, Du H, Lai J-S, Rosen S, et al. Measuring health-related quality of life in leukemia: the Functional Assessment of Cancer Therapy-Leukemia (FACT-Leu) Questionnaire, Value in Health, in press.
20. SAS 9.2 2008, SAS Institute Inc.
21. Cortes J. Natural history and staging of chronic myelogenous leukemia. Hematol Oncol Clin North Am 2004, 18:569-584. viii.